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Abstract: In this study, we assessed the potential use of the 1β-hydroxy-deoxycholic acid (1β-OH-
DCA) to deoxycholic acid (DCA) urinary metabolic ratio (UMR) as a CYP3A metric in ten male
healthy volunteers. Midazolam (MDZ) 1 mg was administered orally at three sessions: alone (control
session), after pre-treatment with fluvoxamine 50 mg (12 h and 2 h prior to MDZ administration),
and voriconazole 400 mg (2 h before MDZ administration) (inhibition session), and after a 7-day
pre-treatment with the inducer rifampicin 600 mg (induction session). The 1β-OH-DCA/DCA UMR
was measured at each session, and correlations with MDZ metrics were established. At baseline,
the 1β-OH-DCA/DCA UMR correlated significantly with oral MDZ clearance (r = 0.652, p = 0.041)
and Cmax (r = −0.652, p = 0.041). In addition, the modulation of CYP3A was reflected in the 1β-
OH-DCA/DCA UMR after the intake of rifampicin (induction ratio = 11.4, p < 0.01). During the
inhibition session, a non-significant 22% decrease in 1β-OH-DCA/DCA was observed (p = 0.275).
This result could be explained by the short duration of CYP3A inhibitors intake fixed in our clinical
trial. Additional studies, particularly involving CYP3A inhibition for a longer period and larger
sample sizes, are needed to confirm the 1β-OH-DCA/DCA metric as a suitable CYP3A biomarker.
Keywords: CYP450; phenotyping; CYP3A; bile acid; biomarker
1. Introduction
Macrolide antibiotics, calcium channel blockers, immunosuppressants, benzodiazepines,
and many other compounds are metabolized by the cytochrome P450 3A (CYP3A) en-
zymes [1]. It is estimated that approximately 30% of all marketed drugs are eliminated
through this subfamily [1]. The metabolism of CYP3A substrates may be largely affected
by the important pharmacokinetic variability of these enzymes’ function, leading to serious
therapeutic complications [2,3]. Drug–drug interactions are a major cause of variability in
CYP3A activity [1]. CYP3A can be induced by ligands that bind to the nuclear receptors
PXR and CAR, reducing the drug levels [4]. In contrast, a number of endogenous and ex-
ogenous compounds can also inhibit CYP3A activity, increasing the drug concentrations [5].
For example, the co-administration of CYP3A inhibitors, such as diltiazem, clarithromycin,
or amiodarone, with a statin may cause rhabdomyolysis [6–8]. Genetic polymorphisms
can also strongly influence CYP3A5 activity. In particular, CYP3A5*3, resulting in a non-
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functional protein, is the most frequent variant allele of CYP3A5 [3,9]. Conversely, few
polymorphisms have been described for CYP3A4 [9].
To date, the standard approach for measuring CYP3A activity is phenotyping using a
probe drug, taking into account the environmental component that explains most of the
enzymatic variability [10].
One of the first tests developed to assess CYP3A activity was the erythromycin breath
test. After the administration of [14C-N-methyl]-erythromycin, the amount of exhaled
14CO2 is measured, allowing prediction of CYP3A activity [11]. However, the presence
of radiolabeled 14C makes its use in clinical practice more complex [12]. In addition,
erythromycin lacks specificity, as it is also a P-glycoprotein substrate [11].
Currently, midazolam (MDZ) is considered as the gold standard for measuring CYP3A
activity. The biotransformation of MDZ into 1′-hydroxy-midazolam (OH-MDZ) is mediated
exclusively through CYP3A, and MDZ is not a substrate for the main drug transporters [13].
However, phenotyping using MDZ requires the administration of an exogenous substance,
which is not always well received by patients and not completely risk-free [14].
CYP3A enzymes are known to metabolize endogenous sterol lipids, including cor-
tisol, cortisone, and dehydroepiandrosterone [15]. The metabolism of cholesterol into
4β-hydroxy-cholesterol has also been described as an endogenous CYP3A probe, but the
long half-life of this latter may, to some extent, affect its use for the detection of rapid
changes in CYP3A activity [16]. More recently, five acyl-carnitines derivatives have been
identified as CYP3A biomarkers using untargeted metabolomics [17]. Several multivariate
equations using one or more of these markers described above have been developed to
optimize the prediction of CYP3A activity through MDZ clearance (CL) [15]. At baseline,
an equation using 6β-hydroxy-cortisol to cortisol and 6β-hydroxy-cortisone to cortisone
urinary metabolic ratios as well as sex as covariates explains 26.1% of the variation in
MDZ CL [18].
The detoxification of bile acids is primarily regulated by the CYP3A4 enzyme in
humans. This enzyme protects against the cytotoxicity of bile acids exacerbated at high
concentration levels [19,20]. In fact, rifampicin, a strong inducer of CYP3A, can be used to
treat some cholestatic conditions via the stimulation of the hydroxylation of bile acids [20].
Several years ago, Bodin et al. [20] observed significant amounts of 1β-hydroxy-deoxycholic
acid (1β-OH-DCA), a secondary bile acid, in the urine samples from five patients treated
with carbamazepine compared to ten healthy volunteers. Then, it was demonstrated
by Hayes et al. [21] that deoxycholic acid (DCA) is specifically metabolized into 1β-OH-
DCA by CYP3A4 and CYP3A7 using recombinant human CYP450 enzymes. In contrast,
CYP3A5 isoenzyme seems not or poorly involved in the 1β-hydroxylation of DCA (around
10–50 times lower) [21–23]. DCA and 1β-OH-DCA can be conjugated to glycine, tau-
rine, glucuronic acid, and sulfate in human hepatocytes. For both bile acids, the glycine
conjugate appears to be the major metabolite, as reported by Hayes et al. [21]. In the
study of Hayes et al. [21], they also measured the 1β-OH-DCA to DCA urinary metabolic
ratio (UMR) in a sample from a carbamazepine-treated patient that was 7-fold higher
than that of a control sample (pooled urine from six healthy controls). The authors con-
cluded that further studies should be conducted to evaluate the promising ability of the
1β-OH-DCA/DCA UMR to phenotype the CYP3A4 enzyme.
Therefore, the objective of our work was to provide additional data concerning the
couple 1β-OH-DCA/DCA in human urine. The study consisted of analyzing urine samples
from ten healthy male volunteers receiving oral MDZ (as part of a phenotyping cocktail)
alone, after inhibition, and after the induction of CYP3A, in order to measure the impact on
the 1β-OH-DCA/DCA ratio and to verify the correlation with MDZ, which is the model
substrate drug for CYP3A activity.
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2. Materials and Methods
2.1. Study Design and Population
Data and samples were extracted from another study involving ten healthy male
volunteers, with the primary objective of evaluating whether the capillary dried blood
spot sampling method was appropriate for the simultaneous phenotyping of CYP450 and
P-glycoprotein using a cocktail approach. More details about the study have been described
elsewhere [24].
All the subjects were non-smokers, had normal liver function tests, and were not
taking any drugs that affect CYP450 activity. In addition, they were not allowed to drink
grapefruit juice for at least one week before and for the duration of the clinical trial.
Figure 1 describes the study timeline for this sub-study.
Figure 1. Study timeline. Midazolam 1 mg, as part of the Geneva cocktail, was orally administered on days 1, 8, and
22. Fluvoxamine 50 mg was administered 12 h and 2 h before the administration of midazolam (inhibition session).
Voriconazole 400 mg was administered 2 h before the administration of midazolam (inhibition session). Rifampicin 600 mg
was administered once daily for seven days until the evening before the administration of midazolam (induction session).
Healthy volunteers were administered, as part of the Geneva cocktail, MDZ 1 mg for
CYP3A phenotyping at baseline (control session). During the inhibition session, partici-
pants received MDZ 1 mg after fluvoxamine intake (50 mg, two doses 12 h and 2 h before
MDZ administration) and voriconazole intake (400 mg, one dose 2 h before MDZ adminis-
tration) [24]. MDZ 1 mg was also received after a pretreatment with the inducer rifampicin
(600 mg, one tablet every evening for seven days until the evening before administration of
MDZ) (induction session). Urine samples were collected over 8 h after MDZ administration
at each session. Venous blood samples (3 mL) were collected before (time 0) as well as
0.5, 1, 2, 3, 4, 6, and 8 h after probe drug administration. Breakfast and lunch were served
approximately 1 h and 4 h, respectively, after the blood sampling. The trial is registered at
http://www.clinicaltrials.gov (NCT01731067).
2.2. Quantification of Exogenous and Endogenous Probes
Analyses of MDZ and OH-MDZ in plasma were performed using a single reverse-
phase high-performance liquid chromatography coupled with tandem mass spectrometry
(LC-MS/MS) method as described in the study of Bosilkosvka et al. [25].
Urinary DCA and 1β-OH-DCA were quantified according to the method described
by Hayes et al. [21] with some modifications. The LC-MS/MS quantification of DCA and
DCA-D4 was performed using calibration standards purchased from Sigma (St. Louis,
MO, USA), and from Expert Synthesis Solutions (London, ON, Canada) for 1β-OH-DCA
and 1β-OH-DCA-D4. To 300 µL of urine samples, 2 µL of the internal standards (IS) stock
solution (3000 ng/mL DCA-D4 and 1β-OH-DCA-D4 in methanol) was added. Then, 225 µL
of 0.1 M sodium acetate buffer (pH 5.6), 8 µL of β-glucuronidase/arylsulfatase from Helix
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pomatia (Roche), and 75 µL of choloylglycine hydrolase from Clostridium perfringens
(0.2 U/µL) (Sigma) were are also added before incubation overnight at 37 ◦C.
After incubation, 300 µL of acetonitrile (ACN) were added, and samples were cen-
trifuged at 4000× g for 20 min. The supernatant was evaporated under nitrogen at a
reduced volume of less than 600 µL. Samples were acidifed with 750 µL of water with
formic acid 0.1%. Then, analytes extraction was performed by Solid Phase Extraction (SPE)
using Oasis MAX cartridges (Waters). MAX cartridges were conditioned with methanol
(1 mL) and equilibrated with water (1 mL). Samples were passed through the MAX car-
tridges followed by washing with 1 mL of water. All analytes were finally eluted by
isopropanol/ACN (6:4) (1 mL). The eluates were evaporated to dryness under a stream of
nitrogen and dissolved in 80 µL of ACN 10% before injection into the LC-MS/MS system.
Along with the urine samples (including hydrolysis and SPE), standard solutions of DCA
and 1β-OH-DCA were prepared in 0.1 M sodium acetate buffer (pH 5.6) at concentrations
between 0.1 and 1000 ng/mL with IS [26,27].
LC-MS/MS analyses were carried out using an Agilent 1290 Infinity series LC system
from Agilent (Paolo Alto, CA, USA) coupled to a 6500 QTtrap® triple quadrupole linear ion
trap mass spectrometer from AB Sciex equipped with an electrospray ionization (Darmstadt,
Germany). Separation was performed with a Kinetex® C18 column (50 × 2.1 mm, 2.6 µm)
from Phenomenex (Brechbühler, Switzerland). Analyst software (version 1.6.2) was used
for system control, data acquisition, and quantification. A linear gradient was applied with
a mobile phase composed of (A) water containing 0.1% acetic acid and (B) ACN containing
0.1% acetic acid. Gradient elution was performed at a 500 µL/min flow rate as follows:
0–1.0 min 28% B, 1.0–4.5 from 28% to 30% B, 4.5–7.5 from 30% to 55% B, 7.5–7.6 min from
55% to 90% B, 7.6–8.6 min 90% B, 8.6–8.7 min from 90% to 28% B, and 8.7–10 min 28%
B. The injection volume was set at 10 µL. Detection of analytes was obtained in negative
mode detection using multiple reaction monitoring (MRM). Most of the unconjugated
bile acids, such as DCA and 1β-OH-DCA, do not fragment when subjected to collision-
induced dissociation. Therefore, we used a MS/MS transition without fragmentation
as performed in previous studies [28–30]. Values of QTrap parameters were as follows:
curtain gas = 40 psi, collision gas = high, IonSpray voltage = 4500 V, temperature = 550 ◦C,
ion source gas 1 = 60 psi, ion source gas 2 = 60 psi. The MRM transitions for each analyte
and IS, and their corresponding optimum MS parameters are described below in Table 1.
Accuracy of quality control samples was within 85% and 115% and both intra-day and
inter-day variabilities did not exceed 15%.
Table 1. LC–MS/MS settings for the analytes and their respective internal standards (IS).
Compound MRM Collision Energy (V) Declustering Potential (V) Cell Exit Potential (V)
DCA 391.2→ 391.2 −20 −160 −17
DCA-D4 395.2→ 395.2 −20 −160 −17
1β-OH-DCA 407.2→ 407. 2 −18 −200 −29
1β-OH-DCA-D4 411.3→ 411.3 −18 −200 −29
2.3. Statistical Analysis
The pharmacokinetic parameters of MDZ were obtained by standard noncompart-
mental methods using WinNonlin version 6.2.1 (Pharsight, Mountain View, CA, USA). The
following MDZ metrics were measured:
• Oral midazolam clearance (oral MDZ CL)
• 1′-hydroxy-midazolam AUC0–8 to midazolam AUC0–8 ratio (AUC8 OH-MDZ/AUC8 MDZ)
• 1′-hydroxy-midazolam to midazolam metabolic ratio at 1 and 2 h (OH-MDZ/MDZ MR)
• Midazolam maximum blood concentration (MDZ Cmax).
J. Pers. Med. 2021, 11, 150 5 of 13





For example, the inhibition ratio of the 1β-OH-DCA/DCA UMR was calculated
as below:
Inhibition ratio UMR 1β−OH−DCA/DCA = UMR 1β−OH−DCA/DCAafter inhibition
UMR 1β−OH−DCA/DCAbefore inhibition
(2)





The results are presented as geometric means with 95% confidence intervals. Com-
parisons of intersessions values were performed using a Wilcoxon matched-pairs signed
rank test. Pearson’s correlation coefficients were calculated between the log-transformed
1β-OH-DCA/DCA and MDZ pharmacokinetic parameters. All statistical analyses were




Ten healthy male volunteers were enrolled and completed the study. They were
aged between 20 and 36 years of age (median age: 23) with a body mass index (BMI)
between 19.9 and 24.4 (median BMI: 22.0) (see the research article by Bosilkovksa et al. [24]
for more details).
3.2. Exogenous and Endogenous CYP3A Phenotyping Metrics
Oral MDZ CL decreased significantly after a dose of fluvoxamine (50 mg) 12 h prior
to MDZ administration, followed by a second dose of fluvoxamine (50 mg) taken concomi-
tantly with voriconazole (400 mg) 2 h before MDZ administration (Figure 2).
Figure 2. Oral midazolam clearance in ten mal volunteers who received 1 mg midazolam orally at baseline and after (a)
inhibition by voriconazole and fluvoxamine, and (b) induction by rifampicin. Error bars represent the standard deviations
of log-transformed oral midazolam clearance and mean values are displayed with a circle. CL, clearance; MDZ, midazolam.
** p < 0.01
All pharmacokinetic parameters of MDZ before and after the ingestion of inhibitors
and the inducer are presented in Table 2.
J. Pers. Med. 2021, 11, 150 6 of 13
Table 2. Pharmacokinetic parameters of endogenous and exogenous probes before and after the ingestion of inhibitors and
the inducer, including inhibition and induction ratios.
Baseline Inhibition Inhibition Ratio Induction Induction Ratio
UMR1β-OH-DCA/DCA 0.25 (0.13–0.45) 0.19 (0.09–0.41) 0.78 (0.52–1.2) 2.8 (1.3–6.0) 11.4 ** (6.3–20.7)
Urinary DCA
excretion (µg/8 h) 63.3 (27.6–145.1) 50.2 (22.7–110.8) 0.79 (0.40–1.6) 22.1 (9.2–52.8) 0.35 * (0.13–0.92)
Urinary1β-OH-DCA
excretion (µg/8 h) 15.5 (5.8–41.3) 9.6 (4.1–22.5) 0.62 (0.26–1.5) 61.8 (30.9–123.3) 4.0 * (1.4–11.0)
Oral MDZ CL (L/h) 143.0 (107.1–191.0) 24.0 (19.7–29.3) 0.17 ** (0.13–0.22) 3296 (2351–4622) 23.1 ** (17.3–30.7)
AUC8 OH-MDZ/AUC8 MDZ 0.45 (0.36–0.58) 0.17 (0.14–0.22) 0.38 ** (0.30–0.47) 2.4 (2.0–2.9) 5.4 ** (4.2–6.8)
OH-MDZ/MDZ MR at 1 h 0.47 (0.37–0.58) 0.21 (0.17–0.27) 0.45 ** (0.36–0.56) 2.4 (2.0–2.8) 5.1 ** (4.2–6.3)
OH-MDZ/MDZ MR at 2 h 0.44 (0.33–0.59) 0.22 (0.17–0.28) 0.49 ** (0.38–0.65) 2.6 (2.2–3.0) 6.0 ** (4.3–8.3)
MDZ Cmax (ng/mL) 3.1 (2.3–4.2) 11.7 (9.2–14.9) 3.7 ** (2.7–5.2) 0.15 (0.10–0.23) 0.05 ** (0.03–0.07)
All data are presented as geometric means with 95% confidence intervals. AUC, area under the plasma concentration–time curve; CL,
clearance; Cmax, maximum plasma concentration; DCA, deoxycholic acid; MDZ, midazolam; MR, metabolic ratio; OH-MDZ, 1′-hydroxy-
midazolam; UMR, urinary metabolic ratio; 1β-OH-DCA, 1β-hydroxy-deoxycholic acid. * p < 0.05; ** p < 0.01.
MDZ CL decreased significantly by 83% (inhibition ratio = 0.17-fold, 95% confidence
interval (CI) 0.13–0.22, p < 0.01) after the ingestion of CYP3A inhibitors. In the case of
CYP3A induction by rifampicin, oral MDZ CL was significantly increased by 23.1-fold
(95% CI 17.3–30.7, p < 0.01). The magnitude of drug–drug interactions (DDIs) was less
pronounced when the metabolite OH-MDZ is taken into account. For instance, for OH-
MDZ/MDZ MR at 1 h, we measured an inhibition ratio of 0.45 (95% CI 0.36–0.56, p < 0.01)
and an induction ratio of 5.1 (95% CI 4.2–6.3, p < 0.01).
Based on in vitro evidence that DCA is a substrate for CYP3A4, the oral administration
of CYP3A inhibitors is expected to decrease the UMR 1β-OH-DCA/DCA. Such results
were observed but were not significant, as shown in Figure 3 and Table 2 (inhibition ratio = 0.78,
95% CI 0.52–1.2, p > 0.05).
Figure 3. Eight-hour 1β-hydroxy-deoxycholic acid/deoxycholic acid individual urinary metabolic ratios at baseline and
after (a) the inhibition by voriconazole and fluvoxamine, and (b) induction by rifampicin. Error bars represent the standard
deviations of log-transformed 1β-hydroxy-deoxycholic acid (1β-OH-DCA/DCA) and mean values are displayed with a
circle. 1β-OH-DCA/DCA, 1β-hydroxy-deoxycholic acid/deoxycholic acid. ** p < 0.01
Similarly, fluvoxamine and voriconazole caused a non-significant decrease in 1β-OH-
DCA urinary excretion of 38% (inhibition ratio = 0.62, 95% CI 0.26–1.5, p > 0.05). However,
the urinary excretion of DCA was not increased following CYP3A inhibition as theoretically
expected (inhibition ratio = 0.79, 95% CI 0.40–1.6, p > 0.05).
The endogenous ratio was 11.4-fold higher following rifampicin intake, a CYP3A
inducer, compared to baseline (95% CI 6.3–20.7, p < 0.01) (Figure 3 and Table 2). 1β-OH-
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DCA and DCA urinary excretion over 8 h were also significantly increased and decreased,
respectively, during the CYP3A4 induction session, as described in Table 2.
3.3. Correlations
Table 3 shows the results regarding the Pearson’s correlation coefficients between the
log-transformed 1β-OH-DCA/DCA UMR and the log-transformed MDZ metrics, includ-
ing oral CL, Cmax, AUClast ratio, and MR at 1 and 2 h, for each subject at baseline, after
CYP3A inhibition, and after CYP3A induction (sessions measured combined or separately).
Table 3. Correlation of log-transformed urinary 1β-OH-DCA/DCA ratio with log-transformed midazolam-based CYP3A4
metrics at baseline, after inhibition, and after induction.
Baseline Inhibition Induction All Sessions
r p r p r p r p
Oral MDZ CL (L/h) 0.652 0.041 0.336 0.343 0.678 0.031 0.808 <0.0001
AUC8 OH-MDZ/AUC8 MDZ 0.275 0.442 0.172 0.635 0.567 0.088 0.781 <0.0001
OH-MDZ/MDZ MR at 1 h 0.331 0.351 −0.040 0.914 0.720 0.019 0.786 <0.0001
OH-MDZ/MDZ MR at 2 h 0.242 0.500 0.215 0.550 0.500 0.141 0.790 <0.0001
MDZ Cmax (ng/mL) −0.652 0.041 −0.491 0.150 −0.456 0.185 −0.821 <0.0001
AUC, area under the plasma concentration–time curve; CL, clearance; Cmax, maximum plasma concentration; DCA, deoxycholic acid;
MDZ, midazolam; MR, metabolic ratio; OH-MDZ, 1′-hydroxy-midazolam; 1β-OH-DCA, 1β-hydroxy-deoxycholic acid.
Among them, the log-transformed oral MDZ CL and Cmax correlated significantly
with the log-transformed 1β-OH-DCA/DCA UMR at baseline (r = 0.652 and r = −0.652,
respectively, p = 0.041). The log-transformed 1β-OH-DCA/DCA UMR correlated also
significantly with the log-transformed MDZ CL and MR at 1 h after MDZ intake during
the induction session (r = 0.678, p = 0.031 and r = 0.720, p = 0.019, respectively), whereas no
significant correlations were found following inhibition. When taking into account all ses-
sions simultaneously, the log-transformed 1β-OH-DCA/DCA UMR showed a significant
correlation with all MDZ metrics (p < 0.0001).
Figure 4a shows the significant relationship between the log-transformed 1β-OH-
DCA/DCA UMR and the log-transformed oral MDZ CL in participants at baseline only.
Figure 4b displays the significant correlation between the log-transformed 1β-OH-DCA/DCA
UMR and the log-transformed oral MDZ CL in healthy volunteers at baseline, following
inhibition with fluvoxamine/voriconazole and induction with rifampicin.
Figure 4. Correlation between log-transformed 1β-hydroxy-deoxycholic acid/deoxycholic acid urinary metabolic ratio and
oral midazolam clearance after (a) the administration of midazolam alone and after (b) the administration of midazolam
alone and after pretreatment with voriconazole/fluvoxamine or rifampicin. Black circles, baseline; CYP3A4-inhibited phase,
red square; CYP3A4-induced phase, blue triangles. 1β-OH-DCA/DCA, 1β-hydroxy-deoxycholic acid/deoxycholic acid;
CL, clearance; MDZ, midazolam.
J. Pers. Med. 2021, 11, 150 8 of 13
4. Discussion
4.1. CYP3A Induction
Following one week of treatment with 600 mg of rifampicin, a significant 11.4-fold
increase in the endogenous metric 1β-OH-DCA/DCA in human urine compared to baseline
was observed. These results confirmed the observations made by Hayes et al. [21], who
reported a 7-fold higher ratio in the urine of a carbamazepine-treated patient compared to
a control sample. MDZ metrics were also effective in capturing changes in CYP3A activity
among participants who received an inducer. For instance, oral MDZ CL and plasma OH-
MDZ/MDZ MR at 1 h were significantly increased by 23.1-fold and 5.1-fold, respectively,
following rifampicin-mediated induction. The magnitude of CYP3A induction reflected
by the endogenous 1β-OH-DCA/DCA UMR was lower compared to oral MDZ CL but
higher than plasma 1-OH-MDZ/MDZ MR at 1 h. The greater inter-individual variability
observed in the endogenous UMR 1β-OH-DCA/DCA compared to MDZ metrics must be
considered with caution and needs to be assessed in future studies with sufficient sample
sizes. In particular, extrinsic and intrinsic factors potentially influencing this endogenous
metric need to be investigated (e.g., circadian rhythm, pathological state, or fed/fasting
conditions) [32–34]. The 6β-hydroxycortisol/cortisol UMR is another common endogenous
CYP3A metric with high inter-individual variability [35]. Shibasaki et al. [36] demonstrated
that the inter-individual variability was lower when measuring the formation clearance
(CLf) of 6β-hydroxycortisol compared to the UMR, which is likely affected by the variability
in the renal CL of cortisol. Therefore, it may also be relevant to test the CLf of 1β-OH-DCA
from DCA in future studies.
Interestingly, even when analyzed individually, DCA and 1β-OH-DCA showed signif-
icant down- and up-regulation, respectively, during the induction session. Such a pattern
was not necessarily followed by other endogenous CYP3A substrates. For instance, plasma
concentration of cholesterol, a CYP3A substrate metabolized into 4β-hydroxy-cholesterol,
does not appear to decrease, as expected, upon drug induction [37,38]. In the research
article of Kasichayanula et al. [38], the plasma concentration of cholesterol even showed a
tendency to increase following the administration of rifampicin 600 mg over two weeks. As
a result, the ability of plasma 4β-OH-cholesterol/cholesterol to highlight CYP3A induction
may be weaker in comparison with other CYP3A4 metrics [16].
4.2. CYP3A Inhibition
Fluvoxamine, a moderate CYP3A inhibitor, was ingested 12 h and 2 h prior to MDZ
administration, while voriconazole, a potent CYP3A inhibitor, was received as a single
dose 2 h before MDZ administration [39,40]. No significant effect on the endogenous metric
1β-OH-DCA/DCA was observed following inhibitors intake. Urinary 1β-OH-DCA/DCA
ratio and DCA excretion over 8 h were decreased by around 20% and urinary excretion of
1β-OH-DCA over 8 h was decreased by approximately 40% (all p > 0.05). In contrast, MDZ
CL decreased significantly by more than 80% following the intake of CYP450 inhibitors.
Unlike exogenous probes ingested simultaneously with inhibitors, endogenous metabolites
have baseline levels in urine and/or plasma at the time of inhibition. In that case, maximal
capture of the inhibition would occur after at least four times the elimination half-life of
the endogenous metabolite in order to fully eliminate baseline levels beforehand [41]. The
elimination half-life of 1β-OH-DCA is unknown, but it is likely that the CYP3A inhibition
duration in this study (12 h) is not long enough to measure significant changes in the
1β-OH-DCA/DCA UMR.
DCA excretion over 8 h was decreased (rather than increased as expected) following
inhibitors intake, demonstrating the absence of impact of the modulation on this biomarker
in this clinical trial. In this study, enzymatic hydrolysis was performed in order to de-
conjugate DCA and 1β-OH-DCA, including the predominant amidated conjugates using
choloylglycine hydrolase. As performed by Hayes et al. [21], it might be relevant to eval-
uate whether chemical solvolysis to complete desulfation could help to adjust for these
inconsistent results.
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Interestingly, in the manuscript of Shin et al. [37], the three endogenous CYP3A sub-
strates cortisol, cortisone, and cholesterol were also illogically down-regulated during
the inhibition session (ketoconazole 400 mg once daily for four days) in both plasma and
urine samples. Underlying mechanisms related to these observations are unclear. The de-
creased endogenous synthesis of these steroid hormones by the adrenal glands or increased
metabolism may occur to compensate the CYP3A modulation [42,43]. Luo et al. [43] made
the same observations regarding cortisol urinary excretion over 24 h, which was not in-
creased following the oral administration of clarithromycin 250 mg twice daily for five days.
In contrast, in the same study, the area under the concentration-time curve of plasma
endogenous cortisol was significantly higher (+19%, p = 0.04) after CYP3A inhibition
compared to baseline conditions, but there were no explanations for such discrepancies
between plasma and urine [43]. Conversely, the endogenous metabolites, i.e., urinary
6β-hydroxy-cortisol, urinary 6β-hydroxy-cortisone, and plasma 4β-hydroxy-cholesterol,
always seem to be consistently down-regulated during the inhibition phase [16,37,43].
4.3. Correlations
In addition to providing a real-time snapshot of factors influencing the enzymatic
pathway of interest (e.g., inhibition or induction), a probe must correlate with an exogenous
reference probe drug [15]. In this clinical trial, the relationships between the urinary endoge-
nous 1β-OH-DCA/DCA ratio and several MDZ metrics at baseline, after CYP3A inhibition,
and after CYP3A induction were examined. Despite the small size of the study, the signifi-
cant correlations observed at baseline with oral MDZ CL and Cmax are very promising. It
indicates that the endogenous 1β-OH-DCA/DCA UMR is a potential metric to phenotype
CYP3A enzymes, which could possibly replace the need to administer MDZ. Moreover,
Pearson’s correlation coefficients were relatively high between the 1β-OH-DCA/DCA
ratio and oral MDZ CL (r = 0.652, p = 0.041) and Cmax (r = −0.652, p = 0.041), indicating a
strong relationship. Interestingly, during the induction phase, significant correlations were
also observed between the bile acid ratio and MDZ CL (r = 0.678, p = 0.031), and MR at
1 h (r = 0.720, p = 0.019), showing a similar capacity to reflect CYP3A induction between
the different metrics. Such correlations were not observed during the inhibition session,
which is likely due to the lack of inhibitory effects observed on DCA and 1β-OH-DCA, as
described previously, compared to MDZ. When data from control, inhibition, and induction
sessions were used concomitantly, the log-transformed 1β-OH-DCA/DCA UMR correlated
significantly with all MDZ metrics (all p < 0.0001), confirming the ability of this endogenous
marker to predict CYP3A activity when altered by DDIs, in particular CYP3A induction.
In most studies, the other endogenous metrics, e.g., urinary 6β-hydroxy-cortisol/cortisol
ratio, showed no or weak correlation with MDZ metrics under basal conditions [15].
For instance, Luo et al. [43] demonstrated no correlation between urinary 6β-hydroxy-
cortisol/cortisol ratio and MDZ MR after oral administration (single dose of 7.5 mg) in
24 healthy volunteers. In the study by Lee et al. [18], the correlation between MDZ CL
(measured after a single intravenous dose MDZ 1 mg) and 6β-hydroxy-cortisol/cortisol
MR was significant but low (Pearson r = 0.278, p < 0.01) in 100 healthy subjects. Re-
garding plasma 4β-hydroxy-cholesterol, significant but relatively weak correlations have
been described with MDZ CL at baseline, as summarized in two reviews dedicated to
4β-hydroxy-cholesterol [16,44]. Until recently, the highest correlation was reported by
Tomalik-Scharte et al. [45], with Spearman’s rank correlation coefficients of 0.348 observed
between plasma 4β-hydroxy-cholesterol/cholesterol and MDZ CL after the intravenous
administration of MDZ in 50 healthy volunteers. However, lately, a stronger correla-
tion (r = 0.69) has been demonstrated between MDZ MR (single oral dose of 2 mg) and
plasma 4β-hydroxy-cholesterol in 73 study participants (from a nondiabetic and diabetic
population) [46].
Globally, correlations between endogenous and exogenous probes are subject to
large discrepancies between the different studies. These differences can be related to
many factors: the sample size used, the endogenous metric used (normalized versus
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not normalized, MR versus formation CL) and, very importantly, the exogenous metric
used—in particular, its mode of administration (oral versus intravenous). Since intestinal
and hepatic CYP3A activity are not correlated within the same subject, it is important
to use the appropriate probe according what needs to be characterized. In the case of
exogenous probes, oral probes will be used to reflect hepatic and intestinal activity, and
an intravenous probe will be used to reflect hepatic activity only [16,44]. As described
by Penzak et al. [44], endogenous biomarkers represent unusual probes because it is not
known whether they can reflect intestinal metabolism, as they are not administered either
orally or intravenously. Some authors assumed that endogenous CYP3A markers will only
phenotype hepatic activity, and for these reasons, they used intravenous MDZ to establish
correlations [17]. However, as most of the drugs are administered orally, we believe that an
ideal endogenous probe should also reflect CYP3A intestinal metabolism. In this context,
bile acids are promising CYP3A biomarkers, since they are actively reabsorbed in the distal
ileum by the apical sodium-dependent bile acid transporter [47]. DCA is a secondary bile
acid produced through 7-dehydroxylation by gut bacteria of cholic acid (CA), which is
a primary bile acid synthesized from cholesterol into the liver [22]. Then, DCA is likely
recycled in the enterohepatic system, where its biotransformation into the tertiary bile acid
1β-OH-DCA may occur via intestinal and hepatic CYP3A [23]. Thus, it appears appropriate
to correlate the urinary 1β-OH-DCA/DCA ratio with MDZ metrics measured after oral
administration of MDZ (rather than intravenous administration).
5. Conclusions
In this clinical trial, we assessed the suitability of two bile acids, DCA and its metabolite
1β-OH-DCA, to substitute MDZ in order to predict CYP3A activity. Indeed, sub-therapeutic
doses of oral MDZ (1 mg), as used in this clinical trial, help to avoid possible adverse
effects, but phenotyping using exogenous probes still involves cost, reconditioning, and/or
manufacturing (and therefore, a risk of error). In addition, the administration of non-
therapeutic probe drugs can cause ethical challenges in vulnerable individuals, such as
pregnant women or children [48]. For these reasons, the use of an endogenous marker to
phenotype CYP3A activity appears more convenient.
In this study, additional clinical data were provided for the urinary endogenous 1β-
OH-DCA/DCA ratio, which is a promising metric for CYP3A phenotyping first evidenced
by Bodin et al. [20] a few years ago. Significant correlations were obtained between the
urinary 1β-OH-DCA/DCA ratio and some MDZ metrics at baseline and after induction.
This biomarker can also accurately detect changes in CYP3A activity due to enzyme
induction by rifampicin in ten healthy male volunteers. In contrast, we believe that CYP3A
inhibitors were not administered long enough to demonstrate significant changes in the
urinary bile acids levels. Further studies are needed in this regard to validate the use of
the 1β-OH-DCA/DCA couple as an endogenous CYP3A probe. Comparison with other
endogenous CYP3A probes may also be relevant to study in larger sample sizes. Potentially,
a combination with other endogenous CYP3A probes may be considered to improve
the prediction of enzyme activity using multivariate models. Additional investigations
appear also required to understand in more detail the role of intestinal CYP3A in the
metabolism of DCA. The limitations of the current study are that only male volunteers
were included and that subjects were not genotyped for CYP3A4 and CYP3A5 enzymes.
Genotyping was considered irrelevant due to the small sample size and low frequency of
the alleles of interest in the Caucasian population (e.g., CYP3A4*22 and CYP3A5*1) [49].
In a previous study including forty-two healthy volunteers, we observed non-significant
differences in the 1β-OH-DCA/DCA UMR between the CYP3A poor, intermediate, and
extensive metabolizers (manuscript submitted for publication). In vitro, CYP3A5 appears
also minimally involved in the hydroxylation of DCA [21]. Therefore, it seems important to
study this pathway in larger in vivo study cohorts to determine whether this endogenous
biomarker can serve as a selective probe for CYP3A4 phenotyping or whether it is a CYP3A
endogenous probe.
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